Shattuck Labs

Q2 FY2026 EarningsQ2 FY26 results for STTK showed a mixed performance against consensus: GAAP EPS of -$0.12 missed the -$0.117 expected mean (though within the -$0.08 to -$0.18 range), while Net Loss of $15.2M was slightly wider than the $14.9M estimated. Revenue remained at $0 as expected for this clinical-stage biotech. The primary variance stemmed from elevated R&D expenses of $11.7M to support the impending Phase 2b trial for SL-325, though the company bolstered its liquidity significantly, ending the quarter with $208.3M in cash, sufficient to fund operations into 2029.